Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 411

1.

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR).

Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F, Criniti JM, Vásquez G, Massardo L, Duarte M, Barile-Fabris LA, García MA, Amigo MC, Espada G, Catoggio LJ, Sato EI, Levy RA, Acevedo Vásquez EM, Chacón-Díaz R, Galarza-Maldonado CM, Iglesias Gamarra AJ, Molina JF, Neira O, Silva CA, Vargas Peña A, Gómez-Puerta JA, Scolnik M, Pons-Estel GJ, Ugolini-Lopes MR, Savio V, Drenkard C, Alvarellos AJ, Ugarte-Gil MF, Babini A, Cavalcanti A, Cardoso Linhares FA, Haye Salinas MJ, Fuentes-Silva YJ, Montandon de Oliveira E Silva AC, Eraso Garnica RM, Herrera Uribe S, Gómez-Martín D, Robaina Sevrini R, Quintana RM, Gordon S, Fragoso-Loyo H, Rosario V, Saurit V, Appenzeller S, Dos Reis Neto ET, Cieza J, González Naranjo LA, González Bello YC, Collado MV, Sarano J, Retamozo S, Sattler ME, Gamboa-Cárdenas RV, Cairoli E, Conti SM, Amezcua-Guerra LM, Silveira LH, Borba EF, Pera MA, Alba Moreyra PB, Arturi V, Berbotto GA, Gerling C, Gobbi CA, Gervasoni VL, Scherbarth HR, Brenol JCT, Cavalcanti F, Costallat LTL, Da Silva NA, Monticielo OA, Seguro LPC, Xavier RM, Llanos C, Montúfar Guardado RA, Garcia de la Torre I, Pineda C, Portela Hernández M, Danza A, Guibert-Toledano M, Reyes GL, Acosta Colman MI, Aquino AM, Mora-Trujillo CS, Muñoz-Louis R, García Valladares I, Orozco MC, Burgos PI, Betancur GV, Alarcón GS; Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR).

Ann Rheum Dis. 2018 Jul 25. pii: annrheumdis-2018-213512. doi: 10.1136/annrheumdis-2018-213512. [Epub ahead of print]

2.

Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus.

Hruskova Z, Tesar V.

Expert Opin Biol Ther. 2018 Jul 31:1-8. doi: 10.1080/14712598.2018.1504918. [Epub ahead of print]

PMID:
30040494
3.

Immunotherapy of systemic sclerosis.

Katsiari CG, Simopoulou T, Alexiou I, Sakkas LI.

Hum Vaccin Immunother. 2018 Jul 9:1-9. doi: 10.1080/21645515.2018.1491508. [Epub ahead of print]

PMID:
29985736
4.

[Thirteen reasons why B cell may not be the best therapeutic target in systemic lupus erythematosus].

Chiche LY.

Rev Med Interne. 2018 May 28. pii: S0248-8663(18)30574-5. doi: 10.1016/j.revmed.2018.05.005. [Epub ahead of print] French. No abstract available.

PMID:
29853262
5.
6.

[Systemic Lupus Erythematosus (SLE) - New Classification Criteria].

Aringer M, Dörner T.

Dtsch Med Wochenschr. 2018 Jun;143(11):811-814. doi: 10.1055/a-0542-3409. Epub 2018 May 28. German.

PMID:
29807382
7.

Current challenges and opportunities in the management of antibody-mediated rejection in lung transplantation.

Hulbert AL, Pavlisko EN, Palmer SM.

Curr Opin Organ Transplant. 2018 Jun;23(3):308-315. doi: 10.1097/MOT.0000000000000537.

PMID:
29742565
8.

Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosus.

Carreira PL, Isenberg DA.

Rheumatology (Oxford). 2018 Apr 5. doi: 10.1093/rheumatology/key064. [Epub ahead of print]

PMID:
29660084
9.

The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.

Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, Bajema IM, Scherer HU, Toes REM, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO.

J Autoimmun. 2018 Jul;91:45-54. doi: 10.1016/j.jaut.2018.03.003. Epub 2018 Apr 7.

PMID:
29636274
10.

BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.

Shin W, Lee HT, Lim H, Lee SH, Son JY, Lee JU, Yoo KY, Ryu SE, Rhie J, Lee JY, Heo YS.

Nat Commun. 2018 Mar 23;9(1):1200. doi: 10.1038/s41467-018-03620-2.

11.

Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year.

Vinod SS, Reed AB, Maxwell J, Cron RQ, Stoll ML.

Pediatr Rheumatol Online J. 2018 Mar 9;16(1):16. doi: 10.1186/s12969-018-0234-0.

12.

When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies.

Mantegazza R, Antozzi C.

Ther Adv Neurol Disord. 2018 Jan 18;11:1756285617749134. doi: 10.1177/1756285617749134. eCollection 2018. Review. Erratum in: Ther Adv Neurol Disord. 2018 Mar 21;11:1756286418765591.

13.

Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments.

Touma Z, Gladman DD.

Lupus Sci Med. 2017 Dec 17;4(1):e000239. doi: 10.1136/lupus-2017-000239. eCollection 2017. Review.

14.

Belimumab and antipneumococcal vaccination in patients with systemic lupus erythematosus.

Azoicai T, Antoniu S, Caruntu ID, Azoicai D, Antohe I, Gavrilovici C.

Expert Rev Clin Immunol. 2018 Mar;14(3):175-177. doi: 10.1080/1744666X.2018.1429269. Epub 2018 Jan 22.

PMID:
29336179
15.

Biologics in Inflammatory Immune-mediated Systemic Diseases.

Moroncini G, Calogera G, Benfaremo D, Gabrielli A.

Curr Pharm Biotechnol. 2017;18(12):1008-1016. doi: 10.2174/1389201019666171226152448. Review.

PMID:
29278213
16.

Belimumab in the treatment of systemic lupus erythematous: An evidence based review of its place in therapy.

Marcondes F, Scheinberg M.

Autoimmun Rev. 2018 Feb;17(2):103-107. doi: 10.1016/j.autrev.2017.11.013. Epub 2017 Nov 24. Review.

PMID:
29180126
17.

[Lupus erythematosus treatment with belimumab in daily practice: Retrospective study of 15 patients].

Garval E, Pennaforte JL, Jaussaud R, Servettaz A, Bernard P, Reguiai Z.

Ann Dermatol Venereol. 2018 Jan;145(1):5-12. doi: 10.1016/j.annder.2017.07.008. Epub 2017 Nov 4. French.

PMID:
29113694
18.

B Cell-Based Treatments in SLE: Past Experience and Current Directions.

Liossis SC, Staveri C.

Curr Rheumatol Rep. 2017 Nov 4;19(12):78. doi: 10.1007/s11926-017-0707-z. Review.

PMID:
29101479
19.

Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.

Kalunian KC, Urowitz MB, Isenberg D, Merrill JT, Petri M, Furie RA, Morgan-Cox MA, Taha R, Watts S, Silk M, Linnik MD.

Rheumatology (Oxford). 2018 Jan 1;57(1):125-133. doi: 10.1093/rheumatology/kex368.

PMID:
29045736
20.

What can Google and Wikipedia can tell us about a disease? Big Data trends analysis in Systemic Lupus Erythematosus.

Sciascia S, Radin M.

Int J Med Inform. 2017 Nov;107:65-69. doi: 10.1016/j.ijmedinf.2017.09.002. Epub 2017 Sep 14.

PMID:
29029693

Supplemental Content

Loading ...
Support Center